Entitätsagnostische Tumortherapie – Was spricht dafür, was dagegen?

Das zunehmende Verständnis der Onkogenese sowie die immer umfangreichere Diagnostik ermöglichen zunehmend die Detektion von Mutationen, die für die Tumorentwicklung und Progression relevant sind. Daraus resultierend lassen sich Ansatzpunkte für zielgerichtete Therapien ableiten. Die vorliegende Übersichtsarbeit soll mittels Pro- und Kontra-Abschnitten einen Überblick über die Möglichkeiten, aber auch Limitationen entitätsagnostischer Therapieansätze aufzeigen und einen Ausblick in die Zukunft geben.

Schlüsselwörter

Entitätsagnostisch - zielgerichtete Therapie - Molekulares Tumorboard - Basketstudien

• Literatur

• 1 Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov 2022; 12 (01) 31-46
• 2 McFarland CD, Mirny L, Korolev K. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci USA 2014; 111 (42) 15138-15143
• 3 Druker BJ, Talpaz M, Resta D. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14) 1031-1037
• 4 Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung 2020; 198 (06) 897-907
• 5 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11) 783-792
• 6 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 7 McCabe N, Turner NC, Lord CJ. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66 (16) 8109-8115
• 8 Banerjee S, Moore KN, Colombo N. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22 (12) 1721-1731
• 9 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30 (04) 558-566
• 10 Golan T, Hammel P, Reni M. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019; 381 (04) 317-327
• 11 de Bono J, Mateo J, Fizazi K. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382 (22) 2091-2102
• 12 Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15 (12) 731-747
• 13 Doebele RC, Drilon A, Paz-Ares L. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21 (02) 271-282
• 14 Drilon A, Oxnard GR, Tan DSW. et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383 (09) 813-824
• 15 Subbiah V, Wolf J, Konda B. et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23 (10) 1261-1273
• 16 Wirth LJ, Sherman E, Robinson B. et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. Engl J Med 2020; 383 (09) 825-835
• 17 Loriot Y, Schuler MH, Iyer G. et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol 2022; 40: 16
• 18 André T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383 (23) 2207-2218
• 19 Maio M, Ascierto PA, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938
• 20 Sha D, Jin Z, Budczies J. et al. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov 2020; 10 (12) 1808-1825
• 21 Marabelle A, Fakih M, Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21 (10) 1353-1365
• 22 Massard C, Michiels S, Ferté C. et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 2017; 7 (06) 586-595
• 23 Hainsworth JD, Meric-Bernstam F, Swanton C. et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol 2018; 36 (06) 536-542
• 24 Adashek JJ, Subbiah V, Kurzrock R. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends Cancer 2021; 7 (01) 15-28
• 25 Hyman DM, Piha-Paul SA, Won H. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018; 554: 189-194
• 26 Hoadley KA, Yau C, Hinoue T. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cel 2018; 173 (02) 291-304.e6
• 27 Van Cutsem E, Huijberts S, Grothey A. et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol 2019; 37 (17) 1460-1469
• 28 Meric-Bernstam F, Hainsworth J, Bose R. et al. MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. Journal of Clinical Oncology 2021; 39 (15) 3004-3004
• 29 Adashek JJ, Subbiah V, Westphalen CB. et al. R. Cancer: slaying the nine-headed Hydra. Ann Oncol 2023; 34 (01) 61-69
• 30 Trédan O, Wang Q, Pissaloux D. et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol 2019; 30 (05) 757-765
• 31 Le Tourneau C, Delord JP, Gonçalves A. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16 (13) 1324-1334
• 32 Leichsenring J, Horak P, Kreutzfeldt S. et al. Variant classification in precision oncology. Int J Cancer 2019; 145 (11) 2996-3010
• 33 Horak P, Heining C, Kreutzfeldt S. et al. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov 2021; 11 (11) 2780-2795
• 34 Rodon J, Soria JC, Berger R. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 2019; 25 (05) 751-758
• 35 Kato S, Kim KH, Lim HJ. et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun 2020; 11 (01) 4965
• 36 Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci 2021; 22 (09) 4774
• 37 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387 (01) 9-20
• 38 Subbiah V. The next generation of evidence-based medicine. Nat Med 2023;
• 39 Nationales Netzwerk Genomische Medizin Lungenkrebs. www.nngm.de
• 40 Innovationsausschuss beim Gemeinsamen Bundesausschuss. DNPM – Deutsches Netzwerk für Personalisierte Medizin. https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/dnpm-deutsches-netzwerk-fuer-personalisierte-medizin.419